Low-dose prasugrel versus clopidogrel for dual antiplatelet therapy after percutaneous coronary intervention: insights from the STOPDAPT-2 total cohort.
No significant differences were detected in short-term cardiovascular or bleeding outcomes between low-dose prasugrel-based and clopidogrel-based DAPT in patients after PCI without major in-hospital complications.